K. Matoishi et al. / Tetrahedron: Asymmetry 9 (1998) 1097–1102
1101
5-hydroxy-3-cyclohexene-1-carboxylate 3511 was developed as in Scheme 3.12,13 Alkaline treatment of
(1R,5R)-33 and (1S,5S)-34 led to deprotection of the benzoyloxy group, and (1R,5R)-30 and (1S,5S)-
35 (as free carboxylic acid) were produced respectively. Due to a beneficial loss of enantioselectivity
by substituting the benzoyloxy group for the hydroxyl group, the hydrolysis of amide in (1R,5R)-30
proceeded very smoothly under mild conditions (entry 17). In this manner, the enantiomer (1R,5R)-35
could be obtained in a highly enantiomerically enriched state (97% e.e.).
Scheme 3.
References
1. Review: Crosby, J.; Moilliet, J.; Parratt, J. S.; Turner, N. J. J. Chem. Soc., Perkin Trans 1 1994, 1679–1687. Sugai, T.;
Yamazaki, T.; Yokoyama, M.; Ohta, H. Biosci. Biotech. Biochem. 1997, 61, 1419–1427. Recent examples: Hayashi, T.;
Yamamoto, K.; Matsuo, A.; Otsubo, K.; Muramatsu, S.; Matsuda, A.; Komatsu, K. J. Ferment. Bioeng. 1997, 83, 139–145.
Eichhorn, E.; Roduit, J.-P.; Shaw, N.; Heinzmann, K.; Kiener, A. Tetrahedron: Asymmetry 1997, 8, 2533–2536. Meth-Cohn,
O.; Wang, M.-X. Chem. Commun. 1997, 1041–1042.
2. Nishise, H.; Kurihara, M.; Tani, Y. Agric. Biol. Chem. 1987, 51, 2613–2616. Tani, Y.; Kurihara, M.; Nishise, H.; Yamamoto,
K. Agric. Biol. Chem. 1989, 53, 3143–3149. Yamamoto, K.; Ueno, Y.; Otsubo, K.; Yamane, H.; Komatsu, K.; Tani, Y. J.
Ferment Bioeng. 1992, 73, 125–129. Robins, K.; Gilligan, T. Eur. Pat. Appl. EP 502,525 (CA. 118: 37548r); Zimmermann,
T.; Robins, K.; Birch, O. M.; Boehlen, E. Eur. Pat. Appl. EP 524,604 (CA. 118: 211426m).
3. Sugai, T.; Yokoyama, M.; Yamazaki, T.; Ohta, H. Chem. Lett. 1997, 797–798.
4. Chen, C.-S.; Fujimoto, Y.; Girdaukas, G.; Sih, C. J. J. Am. Chem. Soc. 1982, 104, 7294–7299. In the case of meso-substrates,
the e.e. of the products is considered to reflect the relative reaction rate between enantiotopic groups.
20
5. A methyl ester of (1R,6S)-20: m.p. 115–116°C; [α]D −6.0 (c=2.22, CHCl3); IR (nujol) νmax 3350, 1720, 1660, 1610,
1
1200, 1030 cm−1; H NMR δ 2.1–3.3 (m, 6H), 3.70 (s, 3H), 5.6–5.9 (m, 2H), 6.0 (br., 2H); found: C, 58.60; H, 6.77;
N, 7.54. Calc. for C9H13NO3: C, 59.00; H, 7.15; N, 7.65%. HPLC analysis of the corresponding benzyl ester: Chiralcel
OJ, hexane:i-PrOH (9:1); 0.3 mL/min, tR (min): 74.4 (1S,6R), 81.0 (1R,6S). The absolute configuration was confirmed by
preparing an authentic sample from a known half ester (1R,6S)-36: see Kobayashi, S.; Kamiyama, K.; Iimori, T.; Ohno, M.
Tetrahedron Lett. 1984, 25, 2557–2560.
6. Entry 2: HPLC of 37, Chiralcel OJ, hexane–i-PrOH (50:1); 0.5 mL/min, tR (min): 43.4 (1S,2R,3S,4R), 48.2 (1R,2S,3R,4S).
See Murata, M.; Uchida, H.; Achiwa, K. Chem. Pharm. Bull. 1992, 40, 2610–2613. Entry 3: the absolute configuration
and e.e. was related to that in entry 2 by hydrogenation of the product. Entry 4: the absolute configuration and e.e. was
related to that in entry 2. Entry 7: HPLC of 38, Develosil, CHCl3:EtOAc (25:1); 0.55 mL/min, tR (min): 12.1 (1S,6R), 14.0
(1R,6S). See Nagao, Y.; Hagiwara, Y.; Kumagai, T.; Ochiai, M.; Inoue, T.; Hashimoto, K.; Fujita, E. J. Org. Chem. 1986,
51, 2391–2393. Nagao, Y.; Kume, M.; Wakabayashi, R. C.; Nakamura, T.; Ochiai, M. Chem. Lett. 1989, 239–242. Entry 9:
HPLC of 39, Develosil, CHCl3:EtOAc (25:1); 0.55 mL/min, tR (min): 12.8 (1S,2R), 14.0 (1R,2S). Entry 15: HPLC analysis
of the corresponding benzyl ester, Chiralcel OJ, hexane:i-PrOH (50:1); 1.0 mL/min, tR (min): 15.3 (1S,2R), 17.4 (1R,2S).
The absolute configuration was related to that in entries 10–14 by hydrogenation of the product (Fig. 2).
22
7. (1S,5S)-32: [α]D −30.5 (c=0.93, CHCl3), Chiralcel OJ, hexane:i-PrOH (9:1); 0.5 mL/min, tR (min): 48.3 (1R,5R), 64.4
22
(1S,5S). An authentic (1R,5R)-32 from (1R,5R)-33: [α]D +112.8 (c=0.90, CHCl3). (1R,5R)-33: m.p. 159.0–159.5°C;
22
[α]D +73.3 (c=0.94, CHCl3); IR (KBr) νmax 3440, 1710, 1660, 1620, 1600, 1450, 1320, 1285, 1275, 1250, 715 cm−1
;
1H NMR δ 1.94 (dt, J=9.5, 12.5 Hz, 1H), 2.28–2.47 (m, 3H), 2.65–2.73 (m, 1H), 5.66–5.79 (m, 3H), 5.76–5.79 (m, 1H),
5.91–5.96 (m, 1H), 7.41–7.45 (m, 2H), 7.53–7.57 (m, 1H), 8.02–8.05 (m, 2H); found: C, 68.75; H, 6.28; N, 5.79. Calc. for
C14H15NO3: C, 68.56; H, 6.16; N, 5.71%. HPLC: Chiralcel OJ, hexane:i-PrOH (5:1); 0.5 mL/min, tR (min): 19.1 (1R,5R),
22
22.4 (1S,5S). A methyl ester of (1S,5S)-34: [α]D −86.4 (c=1.25, CHCl3); IR (film) νmax 3030, 2950, 1720, 1595, 1580,
1450, 1270, 715 cm−1; 1H NMR δ 1.96 (ddd, J=8.9, 11.9, 12.5 Hz, 1H), 2.34–2.53 (m, 3H), 2.76–2.87 (m, 1H), 3.67 (s,
3H), 5.61–5.68 (m, 1H), 5.75–5.81 (m, 1H), 5.91–5.98 (m, 1H), 7.40–7.56 (m, 3H), 8.02–8.06 (m, 2H); found: C, 69.00;